Grimes & Company, Inc. Intercept Pharmaceuticals, Inc. Transaction History

Grimes & Company, Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2020 May 05, 2020	SELL	$48.35 - $118.68 $113,622 - $278,898	-2,350 Closed	0 $0
Q4 2019 Feb 05, 2020	BUY	$57.36 - $124.1 $134,796 - $291,635	2,350 New	2,350 $291,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Grimes & Company, Inc., based on Form 13F filings with the SEC.

Stay updated on Grimes & Company, Inc. with notifications on news.